CN107488217A - 一种多肽、免疫原性偶联物和流感疫苗 - Google Patents
一种多肽、免疫原性偶联物和流感疫苗 Download PDFInfo
- Publication number
- CN107488217A CN107488217A CN201710824731.1A CN201710824731A CN107488217A CN 107488217 A CN107488217 A CN 107488217A CN 201710824731 A CN201710824731 A CN 201710824731A CN 107488217 A CN107488217 A CN 107488217A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- amino acid
- protein
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
动物品系 | 性别 | 体重 | 周龄 | 数量(只) |
Balb/c小鼠 | 雌性 | 18~22g | 6~8周 | 10 |
动物品系 | 性别 | 体重 | 周龄 | 数量(只) |
Balb/c小鼠 | 雌性 | 18~22g | 6~8周 | 80 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710824731.1A CN107488217A (zh) | 2017-09-13 | 2017-09-13 | 一种多肽、免疫原性偶联物和流感疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710824731.1A CN107488217A (zh) | 2017-09-13 | 2017-09-13 | 一种多肽、免疫原性偶联物和流感疫苗 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107488217A true CN107488217A (zh) | 2017-12-19 |
Family
ID=60652583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710824731.1A Pending CN107488217A (zh) | 2017-09-13 | 2017-09-13 | 一种多肽、免疫原性偶联物和流感疫苗 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107488217A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114057847A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057850A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057844A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057849A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057848A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1756562A (zh) * | 2003-03-07 | 2006-04-05 | 麦克公司 | 流感病毒疫苗 |
CN1838967A (zh) * | 2002-12-10 | 2006-09-27 | 洛伦蒂斯有限公司 | 稳定的免疫原性HBc嵌合体颗粒 |
CN101080239A (zh) * | 2003-02-21 | 2007-11-28 | 洛伦蒂斯有限公司 | 作为慢性肝炎治疗性疫苗的稳定化HBc嵌合体颗粒 |
CN101309699A (zh) * | 2005-08-31 | 2008-11-19 | 塞尔德克斯医疗有限公司 | 稳定化的病毒样颗粒和表位展示系统 |
WO2013036973A2 (en) * | 2011-09-09 | 2013-03-14 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
CN106279379A (zh) * | 2016-09-13 | 2017-01-04 | 华兰生物工程股份有限公司 | 一种免疫原HM4‑M2e及其制备方法与应用 |
-
2017
- 2017-09-13 CN CN201710824731.1A patent/CN107488217A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1838967A (zh) * | 2002-12-10 | 2006-09-27 | 洛伦蒂斯有限公司 | 稳定的免疫原性HBc嵌合体颗粒 |
CN101080239A (zh) * | 2003-02-21 | 2007-11-28 | 洛伦蒂斯有限公司 | 作为慢性肝炎治疗性疫苗的稳定化HBc嵌合体颗粒 |
CN1756562A (zh) * | 2003-03-07 | 2006-04-05 | 麦克公司 | 流感病毒疫苗 |
CN101309699A (zh) * | 2005-08-31 | 2008-11-19 | 塞尔德克斯医疗有限公司 | 稳定化的病毒样颗粒和表位展示系统 |
WO2013036973A2 (en) * | 2011-09-09 | 2013-03-14 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
CN106279379A (zh) * | 2016-09-13 | 2017-01-04 | 华兰生物工程股份有限公司 | 一种免疫原HM4‑M2e及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
MAWIEH HAMAD: "Universal vaccines: shifting to one for many or shooting too high too soon!", 《PMIS》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114057847A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057850A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057844A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057849A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057848A (zh) * | 2020-08-07 | 2022-02-18 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057848B (zh) * | 2020-08-07 | 2023-11-21 | 清华大学 | 一种预防新型冠状病毒肺炎covid-19的多肽、免疫原性偶联物及其用途 |
CN114057847B (zh) * | 2020-08-07 | 2024-04-02 | 清华大学 | 一种预防新型冠状病毒covid-19的多肽、免疫原性偶联物及其用途 |
CN114057850B (zh) * | 2020-08-07 | 2024-04-02 | 清华大学 | 一种预防新型冠状病毒covid-19的多肽、免疫原性偶联物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107488218A (zh) | 一种多肽、免疫原性偶联物和流感疫苗 | |
CN107488217A (zh) | 一种多肽、免疫原性偶联物和流感疫苗 | |
CN113150084B (zh) | 一种纳米化的冠状病毒抗原及其应用 | |
CN113150083B (zh) | 重组禽流感亚单位疫苗及其制备方法 | |
CN101879312B (zh) | 广谱型流感疫苗及其制备方法 | |
CN102397559A (zh) | 广谱型流感疫苗及其制备方法 | |
CN107522777A (zh) | 用于预防或治疗流感病毒的多肽、免疫原性偶联物及用途 | |
US20170166612A1 (en) | Method for enhancing immunogenicity of epitope peptide of hpv antigen, virus-like particle, and method for preparing hpv vaccine | |
Sazegari et al. | Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice | |
CN109966483A (zh) | 一种基于铁蛋白的多抗原通用流感疫苗及其制备方法和应用 | |
CN115340609A (zh) | 一种口蹄疫病毒多抗原表位融合蛋白、蛋白笼纳米颗粒及其制备方法 | |
CN105175549A (zh) | 一种流感嗜血杆菌融合蛋白及其构建方法与应用 | |
CN102134279B (zh) | 融合蛋白及其编码基因与应用 | |
CN106279379B (zh) | 一种免疫原HM4-M2e及其制备方法与应用 | |
Li et al. | Recombinant protein comprising multi-neutralizing epitopes induced high titer of antibodies against influenza A virus | |
Chen et al. | Spy&IAC enables specific capture of SpyTagged proteins for rapid assembly of plug-and-display nanoparticle vaccines | |
CN114057850B (zh) | 一种预防新型冠状病毒covid-19的多肽、免疫原性偶联物及其用途 | |
CN112316130A (zh) | 一种SARS-CoV2粘膜免疫疫苗及其应用 | |
CN111848815A (zh) | 猪戊型肝炎基因4型病毒和猪口蹄疫o型病毒中和抗原表位嵌合蛋白及其制备方法与应用 | |
AUVINEN et al. | Mapping of antigenic sites of coxsackievirus B3 by synthetic peptides | |
Zou et al. | Self-assembly polymerization enhances the immunogenicity of influenza M2e peptide | |
CN106337038B (zh) | 一种通过转肽酶剪切制备疫苗的方法及其应用 | |
WO2023151446A1 (zh) | β属冠状病毒融合重组蛋白及其制备方法和应用 | |
CN113527443B (zh) | 甲型流感病毒pb1蛋白t细胞表位多肽片段及其应用 | |
CN114106204B (zh) | 一种具有多种甲型流感病毒免疫原性的融合蛋白及其制备与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: No. 1, No. 1, No. 1, Hua Lan Boulevard a, Henan, Henan Applicant after: Hualan biological vaccine Co.,Ltd. Applicant after: HUALAN GENETIC ENGINEERING Co.,Ltd. Applicant after: HUALAN BIOLOGICAL ENGINEERING Inc. Applicant after: HUALAN BIOLOGICAL ENGINEERING TECHNOLOGY (BEIJING) Co.,Ltd. Address before: No. 1, No. 1, No. 1, Hua Lan Boulevard a, Henan, Henan Applicant before: HUALAN BIOLOGICAL BACTERIN Co.,Ltd. Applicant before: HUALAN GENETIC ENGINEERING Co.,Ltd. Applicant before: HUALAN BIOLOGICAL ENGINEERING Inc. Applicant before: HUALAN BIOLOGICAL ENGINEERING TECHNOLOGY (BEIJING) Co.,Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200805 Address after: No. 1, No. 1, No. 1, Hua Lan Boulevard a, Henan, Henan Applicant after: Hualan biological vaccine Co.,Ltd. Address before: No. 1, No. 1, No. 1, Hua Lan Boulevard a, Henan, Henan Applicant before: Hualan biological vaccine Co.,Ltd. Applicant before: HUALAN GENETIC ENGINEERING Co.,Ltd. Applicant before: HUALAN BIOLOGICAL ENGINEERING Inc. Applicant before: HUALAN BIOLOGICAL ENGINEERING TECHNOLOGY (BEIJING) Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171219 |
|
RJ01 | Rejection of invention patent application after publication |